Skip to main content

CORRECTION article

Front. Mol. Neurosci., 30 November 2021
Sec. Molecular Signalling and Pathways
Volume 14 - 2021 | https://doi.org/10.3389/fnmol.2021.814907
This article is part of the Research Topic Human-based models to decipher the mechanisms of brain diseases View all 9 articles

Corrigendum: Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13

This article is a correction to:

  1. Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13

    1. Read original article
\nAna Caroline Brambilla FalvellaAna Caroline Brambilla Falvella1Bradley Joseph SmithBradley Joseph Smith1Licia C. Silva-CostaLicia C. Silva-Costa1Aline G. F. ValenaAline G. F. Valença1Fernanda CrunfliFernanda Crunfli1Antonio W. ZuardiAntonio W. Zuardi2Jaime E. HallakJaime E. Hallak2Jos A. CrippaJosé A. Crippa2Valria de Almeida Valéria de Almeida1*Daniel Martins-de-Souza,,, Daniel Martins-de-Souza1,3,4,5*
  • 1Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP), Campinas, Brazil
  • 2Department of Neurosciences and Behavior, Faculty of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil
  • 3Instituto Nacional de Biomarcadores em Neuropsiquiatria (INBION) Conselho Nacional de Desenvolvimento Científico e Tecnológico, São Paulo, Brazil
  • 4Experimental Medicine Research Cluster (EMRC), University of Campinas, Campinas, Brazil
  • 5D'Or Institute for Research and Education (IDOR), São Paulo, Brazil

A Corrigendum on
Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13

by Falvella, A. C. B., Smith, B. J., Silva-Costa, L. C., Valença, A. G. F., Crunfli, F., Zuardi, A. W., Hallak, J. E., Crippa, J. A., Almeida, V., and Martins-de-Souza, D. (2021). Front. Mol. Neurosci. 14:673144. doi: 10.3389/fnmol.2021.673144

In the original article, information from the Data Availability statement was mistakenly omitted. The corrected Data Availability Statement is below.

The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD028419.

The authors apologize for the error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: benztropine, haloperidol, clozapine, MO3.13 cell line, phytocannabinoid, proteome, schizophrenia

Citation: Falvella ACB, Smith BJ, Silva-Costa LC, Valença AGF, Crunfli F, Zuardi AW, Hallak JE, Crippa JA, Almeida V and Martins-de-Souza D (2021) Corrigendum: Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front. Mol. Neurosci. 14:814907. doi: 10.3389/fnmol.2021.814907

Received: 14 November 2021; Accepted: 15 November 2021;
Published: 30 November 2021.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2021 Falvella, Smith, Silva-Costa, Valença, Crunfli, Zuardi, Hallak, Crippa, Almeida and Martins-de-Souza. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Valéria de Almeida, val_farmac@yahoo.com.br; Daniel Martins-de-Souza, dmsouza@unicamp.br

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.